Dr Marcela Maus
@MarcelaMaus
ID:4384685715
05-12-2015 16:26:48
127 Tweets
1,0K Followers
151 Following
Clinical trial results from show 'dramatic & rapid' regression of glioblastoma after next generation CAR T therapy at the Mass General Cancer Center with Dr Marcela Maus, MD, director of the Cellular Immunotherapy Program. Learn more: spklr.io/6011Wf0l NEJM
Today, NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma . Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators MGH Neurosurgery and Mass General Cancer Center!
nej.md/3VnjUIq
Not all people respond equally well to CAR-T cell therapy, a kind of immunotherapy that has dramatically improved blood cancer treatment. A new single-cell study by researchers at the Broad, MassGeneral News, and Dana-Farber could help reveal why. broad.io/carttherapy0912
A collaborative team at the Broad Institute describes distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell #lymphoma .
🥼 Dr Marcela Maus Gaddy Getz Mark Leick Katie Maurer Satyen Gohil
Learn more: go.nature.com/3eQtbWc
.MassGeneral News researchers, led by ASGCT Board Member Dr Marcela Maus & Associate Member Mark Leick, developed a novel treatment strategy that has the potential to bring the benefits of #CART #celltherapy to patients with acute myeloid #leukemia ( #AML ). bit.ly/3kq9JPP
Exciting new CAR design for AML from our lab! Now online Cancer Cell Mass General Cancer Center Mass General Brigham Innovation
Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC Cancer Cell cell.com/cancer-cell/fu…
✨ New today in nature!
Dr. Dr Marcela Maus at Harvard Medical School and colleagues demonstrated that liquid 💧 and solid 🧊 tumors differ in their interactions with #CAR T cells, particularly in regards to the IFNγR pathway.
go.nature.com/3xr4bfz
Critical findings from a study nature led by Dr Marcela Maus differentiating CAR T-cell efficacy against liquid versus solid tumors like #Glioblastoma ...INFg is the key!
nature.com/articles/s4158…
Online at @nature: “CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours” by Dr Marcela Maus and colleagues nature.com/articles/s4158…
Today #AACR22 , don’t miss Nicholas Haradhvala presenting on single-cell analysis of cellular dynamics underlying clinical response to #CARTcell therapy in #collab work with Cathy Wu and Dr Marcela Maus labs (Talk #3575). Then, read more of the story @medrxiv: medrxiv.org/content/10.110…
When a pediatric oncologist gives a plenary talk at #AACR2022 , you see evidence of CAR-T cell success with improvement in coloring skills. So proud and grateful to our brave patients. Congrats to Majzner_Lab for an amazing talk. Sneha Ramakrishna Mackall Lab Michelle Monje🎗️
Mechanisms of CAR T-cell therapy + #immunotherapy being discussed today at #AACR22 by St. Baldrick's Foundation Stand Up To Cancer #PediatricCancer Dream Team Co-leader Dr. Crystal Mackall + Innovative Rsch Grant Recipient Dr Marcela Maus Mackall Lab Stanford Cancer Institute MassGeneral News
abstractsonline.com/pp8/#!/10517/s…
Decades of studying the immune system's response to a virus help #researchers discover new treatments and potential cures to deadly diseases. Learn how this team at Mass General Brigham is working to change medicine. nyti.ms/3JX7iie
New #JITC short report: Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) bit.ly/3JOiwqc Matthew Frigault Dr Marcela Maus
